Oruka Therapeutics (ORKA) stock: insider trades, news & valuation
Heavy selling
Close · Oct 9, 2026
$82.11
+6.2% on the day
+221.4% over 12 months
52-week range $24.49 – $113.08
Share price and insider trades
ORKA closeInsider buyInsider sale
Bought, 12 months$0
Sold, 12 months$336M
Insiders buying0
Insiders selling7
Oruka Therapeutics insider trading at a glance (Oct 9, 2026): in the past 12 months, 0 insiders bought $0 and 7 sold $336M of ORKA stock on the open market.
Get emailed when insiders cluster-buy stocks like ORKA
Free alerts the day a new cluster buy is filed, plus the Monday report of the week's biggest insider trades.
Free · unsubscribe anytime · not investment advice · see a sample issue
ORKA insider buying and selling by quarter
Open-market purchases (green, above the line) and sales (red, below), by trade date.
| Quarter | Bought | Purchases | Sold | Sales |
|---|---|---|---|---|
| Q4 2026 | — | 0 | $2.1M | 3 |
| Q3 2026 | — | 0 | $320M | 50 |
| Q2 2026 | — | 0 | $12.0M | 34 |
| Q1 2026 | — | 0 | $1.4M | 17 |
| Q4 2025 | — | 0 | $214K | 4 |
Valuation, profit and volume
P/E (trailing)n/aSector median —
Market value—
Profit margin—Revenue growth —
Volume vs. 50-day1.1×Last 5 sessions
Insiders' paper profit—On all tracked purchases —
Summary
Over the past 12 months, 0 Oruka Therapeutics, Inc. insiders reported open-market purchases totaling $0, while 7 insiders reported sales totaling $336M. 97 of 108 recorded sales were made under pre-scheduled Rule 10b5-1 trading plans, which are usually less informative than discretionary sales.
Insider transactions
Open-market purchases and sales.
| Filed | Insider | Type | Shares | Price | Value | Since | Score |
|---|---|---|---|---|---|---|---|
| Oct 2SEC | Lawrence Otto KleinCEO | Sell Plan | 16,246931,882 held (−2%) | $83.40 | $1.4M | -1.5% | — |
| Oct 2SEC | Lawrence Otto KleinCEO | Sell Plan | 8,554923,328 held (−1%) | $84.03 | $719K | -2.3% | — |
| Oct 2SEC | Lawrence Otto KleinCEO | Sell Plan | 200923,128 held (−0%) | $84.78 | $17K | -3.1% | — |
| Sep 21SEC | Paul T QuinlanGeneral Counsel | Sell Plan | 3,83233,263 held (−10%) | $93.32 | $358K | -12.0% | — |
| Sep 21SEC | Paul T QuinlanGeneral Counsel | Sell Plan | 2,90037,095 held (−7%) | $92.37 | $268K | -11.1% | — |
| Sep 21SEC | Paul T QuinlanGeneral Counsel | Sell Plan | 2,66729,995 held (−8%) | $95.31 | $254K | -13.8% | — |
| Sep 21SEC | Paul T QuinlanGeneral Counsel | Sell Plan | 60132,662 held (−2%) | $94.44 | $57K | -13.1% | — |
| Sep 21SEC | Arjun AgarwalPresident | Sell Plan | 53314,219 held (−4%) | $95.75 | $51K | -14.2% | — |
| Sep 15SEC | Arjun AgarwalPresident | Sell Plan | 4,05117,720 held (−19%) | $92.41 | $374K | -11.1% | — |
| Sep 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 3,15034,184 held (−8%) | $92.03 | $290K | -10.8% | — |
| Sep 15SEC | Arjun AgarwalPresident | Sell Plan | 3,00021,771 held (−12%) | $91.11 | $273K | -9.9% | — |
| Sep 15SEC | Lawrence Otto KleinCEO | Sell | 2,452923,128 held (−0%) | $95.71 | $235K | -14.2% | — |
| Sep 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 2,38437,334 held (−6%) | $91.10 | $217K | -9.9% | — |
| Sep 15SEC | Arjun AgarwalPresident | Sell Plan | 2,20815,512 held (−12%) | $93.26 | $206K | -12.0% | — |
| Sep 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 1,36632,818 held (−4%) | $92.99 | $127K | -11.7% | — |
| Sep 15SEC | Paul T QuinlanGeneral Counsel | Sell | 1,03929,995 held (−3%) | $95.71 | $99K | -14.2% | — |
| Sep 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 94731,771 held (−3%) | $95.71 | $91K | -14.2% | — |
| Sep 15SEC | Laura Lee SandlerCOO | Sell | 906235,478 held (−0%) | $95.71 | $87K | -14.2% | — |
| Sep 15SEC | Arjun AgarwalPresident | Sell Plan | 56014,752 held (−4%) | $95.71 | $54K | -14.2% | — |
| Sep 15SEC | Arjun AgarwalPresident | Sell Plan | 20015,312 held (−1%) | $94.02 | $19K | -12.7% | — |
| Sep 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 10032,718 held (−0%) | $94.22 | $9K | -12.9% | — |
| Sep 1SEC | Lawrence Otto KleinCEO | Sell Plan | 63,596930,380 held (−6%) | $91.90 | $5.8M | -10.7% | — |
| Sep 1SEC | Lawrence Otto KleinCEO | Sell Plan | 6,604993,976 held (−1%) | $90.79 | $600K | -9.6% | — |
| Sep 1SEC | Lawrence Otto KleinCEO | Sell Plan | 4,800925,580 held (−1%) | $92.44 | $444K | -11.2% | — |
| Sep 1SEC | Laura Lee SandlerCOO | Sell Plan | 4,000236,384 held (−2%) | $92.01 | $368K | -10.8% | — |
| Sep 1SEC | Laura Lee SandlerCOO | Sell Plan | 1,000240,384 held (−0%) | $91.05 | $91K | -9.8% | — |
| Aug 17SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 3,32035,198 held (−9%) | $112.01 | $372K | -26.7% | — |
| Aug 17SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 2,48032,718 held (−7%) | $112.56 | $279K | -27.1% | — |
| Aug 17SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 90038,818 held (−2%) | $109.65 | $99K | -25.1% | — |
| Aug 17SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 30038,518 held (−1%) | $110.52 | $33K | -25.7% | — |
| Aug 14SEC | Paul T QuinlanGeneral Counsel | Sell Plan | 14,69654,274 held (−21%) | $107.97 | $1.6M | -24.0% | — |
| Aug 14SEC | Paul T QuinlanGeneral Counsel | Sell Plan | 10,43468,970 held (−13%) | $107.14 | $1.1M | -23.4% | — |
| Aug 14SEC | Paul T QuinlanGeneral Counsel | Sell Plan | 10,20044,074 held (−19%) | $109.11 | $1.1M | -24.7% | — |
| Aug 14SEC | Paul T QuinlanGeneral Counsel | Sell Plan | 9,19334,881 held (−21%) | $110.00 | $1.0M | -25.4% | — |
| Aug 14SEC | Paul T QuinlanGeneral Counsel | Sell Plan | 3,84731,034 held (−11%) | $111.14 | $428K | -26.1% | — |
| Aug 14SEC | Paul T QuinlanGeneral Counsel | Sell Plan | 3,63079,404 held (−4%) | $106.05 | $385K | -22.6% | — |
| Aug 14SEC | Arjun AgarwalPresident | Sell Plan | 2,35815,312 held (−13%) | $108.46 | $256K | -24.3% | — |
| Aug 14SEC | Arjun AgarwalPresident | Sell Plan | 2,14217,670 held (−11%) | $107.71 | $231K | -23.8% | — |
| Aug 14SEC | Arjun AgarwalPresident | Sell Plan | 2,13221,080 held (−9%) | $105.57 | $225K | -22.2% | — |
| Aug 14SEC | Arjun AgarwalPresident | Sell Plan | 2,10023,212 held (−8%) | $104.67 | $220K | -21.6% | — |
| Aug 14SEC | Arjun AgarwalPresident | Sell Plan | 1,26819,812 held (−6%) | $106.63 | $135K | -23.0% | — |
| Jul 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 3,80333,018 held (−10%) | $86.68 | $330K | -5.3% | — |
| Jul 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 2,49736,821 held (−6%) | $85.86 | $214K | -4.4% | — |
| Jul 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 40039,318 held (−1%) | $84.37 | $34K | -2.7% | — |
| Jul 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 30032,718 held (−1%) | $87.25 | $26K | -5.9% | — |
| Jul 13SEC | Arjun AgarwalPresident | Sell Plan | 5,65615,612 held (−27%) | $84.90 | $480K | -3.3% | — |
| Jul 13SEC | Arjun AgarwalPresident | Sell Plan | 3,74321,268 held (−15%) | $84.26 | $315K | -2.6% | — |
| Jul 13SEC | Arjun AgarwalPresident | Sell Plan | 30015,312 held (−2%) | $85.63 | $26K | -4.1% | — |
| Jul 13SEC | Arjun AgarwalPresident | Sell Plan | 30025,011 held (−1%) | $83.07 | $25K | -1.2% | — |
| Jul 1SEC | Tomas KiselakDirector | Sell | 3,553,4101,131,954 held (−76%) | $84.43 | $300M | -2.7% | — |
| Jul 1SEC | Laura Lee SandlerCOO | Sell Plan | 2,263236,884 held (−1%) | $94.75 | $214K | -13.3% | — |
| Jul 1SEC | Laura Lee SandlerCOO | Sell Plan | 2,237239,147 held (−1%) | $93.85 | $210K | -12.5% | — |
| Jul 1SEC | Laura Lee SandlerCOO | Sell Plan | 500236,384 held (−0%) | $95.47 | $48K | -14.0% | — |
| Jun 22SEC | Arjun AgarwalPresident | Sell Plan | 88816,011 held (−5%) | $80.01 | $71K | +2.6% | — |
| Jun 22SEC | Arjun AgarwalPresident | Sell Plan | 69915,312 held (−4%) | $82.15 | $57K | -0.0% | — |
| Jun 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 5,06433,965 held (−13%) | $69.42 | $352K | +18.3% | — |
| Jun 15SEC | Arjun AgarwalPresident | Sell Plan | 4,34020,554 held (−17%) | $69.85 | $303K | +17.6% | — |
| Jun 15SEC | Arjun AgarwalPresident | Sell Plan | 3,26017,294 held (−16%) | $70.34 | $229K | +16.7% | — |
| Jun 15SEC | Arjun AgarwalPresident | Sell Plan | 1,85924,894 held (−7%) | $68.34 | $127K | +20.1% | — |
| Jun 15SEC | Lawrence Otto KleinCEO | Sell | 1,729925,580 held (−0%) | $69.69 | $120K | +17.8% | — |
| Jun 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 1,63639,029 held (−4%) | $68.38 | $112K | +20.1% | — |
| Jun 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 94732,718 held (−3%) | $69.69 | $66K | +17.8% | — |
| Jun 15SEC | Paul T QuinlanGeneral Counsel | Sell | 73331,034 held (−2%) | $69.69 | $51K | +17.8% | — |
| Jun 15SEC | Laura Lee SandlerCOO | Sell | 600236,384 held (−0%) | $69.69 | $42K | +17.8% | — |
| Jun 15SEC | Arjun AgarwalPresident | Sell Plan | 39516,899 held (−2%) | $69.69 | $28K | +17.8% | — |
| Jun 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 30033,665 held (−1%) | $70.62 | $21K | +16.3% | — |
| Jun 12SEC | Carl DambkowskiDirector | Sell Plan | 22,41751,326 held (−30%) | $70.13 | $1.6M | +17.1% | — |
| Jun 12SEC | Carl DambkowskiDirector | Sell Plan | 12,58338,743 held (−25%) | $70.11 | $882K | +17.1% | — |
| May 22SEC | Carl DambkowskiDirector | Sell Plan | 53,44786,978 held (−38%) | $59.10 | $3.2M | +38.9% | — |
| May 22SEC | Carl DambkowskiDirector | Sell Plan | 38,318140,425 held (−21%) | $58.43 | $2.2M | +40.5% | — |
| May 22SEC | Carl DambkowskiDirector | Sell Plan | 13,23573,743 held (−15%) | $59.97 | $794K | +36.9% | — |
| May 18SEC | Arjun AgarwalPresident | Sell Plan | 4,60017,906 held (−20%) | $59.19 | $272K | +38.7% | — |
| May 18SEC | Arjun AgarwalPresident | Sell Plan | 4,19022,506 held (−16%) | $58.34 | $244K | +40.7% | — |
| May 18SEC | Arjun AgarwalPresident | Sell Plan | 80017,106 held (−4%) | $60.34 | $48K | +36.1% | — |
| May 18SEC | Arjun AgarwalPresident | Sell Plan | 70016,406 held (−4%) | $61.16 | $43K | +34.3% | — |
| May 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 4,80035,577 held (−12%) | $61.56 | $295K | +33.4% | — |
| May 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 2,10033,477 held (−6%) | $62.42 | $131K | +31.5% | — |
| May 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 10033,377 held (−0%) | $63.52 | $6K | +29.3% | — |
| May 1SEC | Laura Lee SandlerCOO | Sell Plan | 2,200239,784 held (−1%) | $62.58 | $138K | +31.2% | — |
| May 1SEC | Laura Lee SandlerCOO | Sell Plan | 1,800237,984 held (−1%) | $64.15 | $115K | +28.0% | — |
| May 1SEC | Laura Lee SandlerCOO | Sell Plan | 400237,284 held (−0%) | $66.06 | $26K | +24.3% | — |
| May 1SEC | Laura Lee SandlerCOO | Sell Plan | 300237,684 held (−0%) | $65.10 | $20K | +26.1% | — |
| May 1SEC | Laura Lee SandlerCOO | Sell Plan | 200237,084 held (−0%) | $67.16 | $13K | +22.3% | — |
| May 1SEC | Laura Lee SandlerCOO | Sell Plan | 100236,984 held (−0%) | $68.48 | $7K | +19.9% | — |
| Apr 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 4,22736,150 held (−10%) | $65.73 | $278K | +24.9% | — |
| Apr 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 2,27333,877 held (−6%) | $66.56 | $151K | +23.4% | — |
| Apr 15SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 50033,377 held (−1%) | $67.38 | $34K | +21.9% | — |
| Mar 17SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 2,90235,195 held (−8%) | $41.20 | $120K | +99.3% | — |
| Mar 17SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 2,92138,097 held (−7%) | $40.11 | $117K | +104.7% | — |
| Mar 17SEC | Lawrence Otto KleinCEO | Sell | 1,729927,309 held (−0%) | $41.30 | $71K | +98.8% | — |
| Mar 17SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 1,17734,018 held (−3%) | $41.94 | $49K | +95.8% | — |
| Mar 17SEC | Paul T QuinlanGeneral Counsel | Sell | 73331,767 held (−2%) | $41.30 | $30K | +98.8% | — |
| Mar 17SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 64133,377 held (−2%) | $41.30 | $26K | +98.8% | — |
| Mar 17SEC | Laura Lee SandlerCOO | Sell | 600236,984 held (−0%) | $41.30 | $25K | +98.8% | — |
| Mar 17SEC | Arjun AgarwalPresident | Sell | 39518,863 held (−2%) | $41.30 | $16K | +98.8% | — |
| Mar 2SEC | Laura Lee SandlerCOO | Sell Plan | 2,675237,584 held (−1%) | $33.81 | $90K | +142.9% | — |
| Mar 2SEC | Laura Lee SandlerCOO | Sell Plan | 2,325240,259 held (−1%) | $33.28 | $77K | +146.7% | — |
| Feb 17SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 6,06434,954 held (−15%) | $32.30 | $196K | +154.2% | — |
| Feb 17SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 93634,018 held (−3%) | $32.78 | $31K | +150.5% | — |
| Jan 16SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 4,3814,137 held (−51%) | $31.56 | $138K | +160.2% | — |
| Jan 16SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 2,6191,518 held (−63%) | $32.24 | $84K | +154.7% | — |
| Jan 2SEC | Laura Lee SandlerCOO | Sell Plan | 8,748209,336 held (−4%) | $28.17 | $246K | +191.5% | — |
| Jan 2SEC | Laura Lee SandlerCOO | Sell Plan | 3,144206,192 held (−2%) | $29.08 | $91K | +182.4% | — |
| Jan 2SEC | Laura Lee SandlerCOO | Sell Plan | 1,108205,084 held (−1%) | $29.75 | $33K | +176.0% | — |
| Dec 19SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 3,0801,518 held (−67%) | $31.58 | $97K | +160.0% | — |
| Dec 19SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 1,7876,090 held (−23%) | $29.62 | $53K | +177.2% | — |
| Dec 19SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 1,4924,598 held (−24%) | $30.70 | $46K | +167.5% | — |
| Dec 19SEC | Joana GoncalvesChief Medical Officer | Sell Plan | 6417,877 held (−8%) | $28.53 | $18K | +187.8% | — |
Insiders at Oruka Therapeutics, Inc.
| Insider | Bought | Sold | Last filing | Score |
|---|---|---|---|---|
| Tomas KiselakDirector | — | $300M | Jul 1, 2026 | — |
| Lawrence Otto KleinCEO | — | $9.4M | Oct 2, 2026 | — |
| Carl DambkowskiDirector | — | $8.6M | Jun 12, 2026 | — |
| Paul T QuinlanGeneral Counsel | — | $6.8M | Sep 21, 2026 | — |
| Joana GoncalvesChief Medical Officer | — | $4.5M | Sep 15, 2026 | — |
| Arjun AgarwalPresident | — | $4.3M | Sep 21, 2026 | — |
| Laura Lee SandlerCOO | — | $1.9M | Sep 15, 2026 | — |
ORKA stock: common questions
Are Oruka Therapeutics, Inc. insiders buying ORKA stock?
In the past 12 months, 0 insiders reported open-market purchases of ORKA worth $0.
Are Oruka Therapeutics, Inc. insiders selling ORKA stock?
7 insiders reported sales worth $336M over the same period.
Where does this data come from?
Every transaction comes from Form 4 filings that insiders must submit to the SEC within two business days of a trade. We pull them from SEC EDGAR every night.
What is ORKA's 52-week range?
Over the past year ORKA has traded between $24.49 and $113.08. It last closed at $82.11 on Oct 9, 2026.